Wnt/β-catenin信号通路在肿瘤耐药中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2016.06.015

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (6): 455-457.doi: 10.3760/cma.j.issn.1673-422X.2016.06.015

Wnt/β-catenin信号通路在肿瘤耐药中的研究进展

移志刚，周开升，蒲彦川，王兴文，王拴科

730030 兰州大学第二医院骨科

收稿日期:2015-08-03 出版日期:2016-06-08 发布日期:2016-04-27
通讯作者: 王拴科 E-mail:wsk2zzy@yahoo.com.cn
基金资助:
甘肃省创新研究群体计划（1308RJIA004）

Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance

Yi Zhigang, Zhou Kaisheng, Pu Yanchuan, Wang Xingwen, Wang Shuanke

Department of Orthopaedics, Second Hospital of Lanzhou University, Lanzhou 730030, China

Received:2015-08-03 Online:2016-06-08 Published:2016-04-27
Contact: Wang Shuanke E-mail:wsk2zzy@yahoo.com.cn
Supported by:
Innovative Research Group Project of Gansu Province (1308RJIA004)

摘要/Abstract

摘要： Wnt/β-catenin信号通路参与肿瘤细胞的增殖、侵袭和转移，并且诱导肿瘤的耐药，是介导组织癌变的关键通路。体外实验表明，靶向抑制Wnt/β-catenin能够增强化疗药物的敏感性。因此对Wnt/β-catenin介导肿瘤耐药的深入研究将为肿瘤的治疗提供可能途径和潜在靶点。

关键词: 肿瘤, 药物耐受性, Wnt/β-catenin信号

Abstract: Wnt/β-catenin signaling pathway participates in cancer cell proliferation, invasion and metastasis and effectively induces drug resistance. It is also the key signal to mediate cancer carcinogenesis. Recent studies in vitro indicate that disturbance of Wnt/βcatenin signaling pathway can increase the sensitivity of the cancer cells to chemotherapeutic drugs. Indepth researches and analysis of tumor drug resistance induced by Wnt/β-catenin will provide potential targets and possible therapeutic means for the treatment of tumors.

Key words: Neoplasms, Drug tolerance, Wnt/β-catenin signaling pathway

移志刚，周开升，蒲彦川，王兴文，王拴科. Wnt/β-catenin信号通路在肿瘤耐药中的研究进展[J]. 国际肿瘤学杂志, 2016, 43(6): 455-457.

Yi Zhigang, Zhou Kaisheng, Pu Yanchuan, Wang Xingwen, Wang Shuanke. Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance[J]. Journal of International Oncology, 2016, 43(6): 455-457.

参考文献

［1］Liu YY, Gupta V, Patwardhan GA, et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling[J]. Mol Cancer, 2010, 9: 145. DOI: 10.1186/1476-4598-9-145. ［2］ Gan SY, Zhong XY, Xie SM, et al. Expression and significance of tumor drug resistance related proteins and betacatenin in esophageal squamous cell carcinoma［J］. Chin J Cancer, 2010, 29(3): 300-305. ［3］ Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome［J］. Cell, 1982, 31(1): 99-109. ［4］ Rijsewijk F, Schuermann M, Wagenaar E, et al. The drosophila homolog of the mouse mammary oncogene int1 is identical to the segment polarity gene wingless［J］. Cell, 1987, 50(4): 649-657. ［5］ Akiyama T. Wnt/betacatenin signaling［J］. Cytokine Growth Factor Rev, 2000, 11(4): 273-282. ［6］ Thomas DW. Bone and cancer［J］. J Pathol, 2010, 220(1): 1-4. ［7］ Ma Y, Ren Y, Han EQ, et al. Inhibition of the Wntβcatenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy［J］. Biochem Biophys Res Commun, 2013, 431(2): 274-279. DOI: 10.1016/j.bbrc.2012.12.118. ［8］ Zhang F, Chen A, Chen J, et al. SiRNAmediated silencing of betacatenin suppresses invasion and chemosensitivity to doxorubicin in MG63 osteosarcoma cells［J］. Asian Pac J Cancer Prev, 2011, 12(1): 239-245. ［9］ Zhang F, Chen A, Chen J, et al. Influence of βcatenin small interfering RNA on human osteosarcoma cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(3): 353-358. DOI: 10.1007/s11596-011-0380-9. ［10］ Morin PJ. Betacatenin signaling and cancer［J］. Bioessays, 1999, 21(12): 1021-1030. ［11］ Wang X, Wu X, Wang C, et al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wildtype p53 through the NFkappaB pathway in MCF7 cells［J］. FEBS Lett, 2010, 584(15): 33923397. DOI: 10.1016/j.febslet.2010.06.033. ［12］ Zhang H, Zhang X, Wu X, et al. Interference of frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/βcatenin pathway［J］. Cancer Lett, 2012, 323(1): 106-113. DOI: 10.1016/j.canlet.2012.03.039. ［13］ Kildal W, Risberg B, Abeler VM, et al. Betacatenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients［J］. Eur J Cancer, 2005, 41(8): 1127-1134. DOI: 10.1016/j.ejca.2005.01.022. ［14］ Cai G, Wang J, Xin X, et al. Phosphorylation of glycogen synthase kinase3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells［J］. Int J Oncol, 2007, 31(3): 657-662. ［15］ Zhao H, Wei W, Sun Y, et al. Interference with the expression of βcatenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model［J］. DNA Cell Biol, 2015, 34(1): 55-62. DOI: 10.1089/dna.2014.2626. ［16］ He B, Barg RN, You L, et al. Wnt signaling in stem cells and nonsmallcell lung cancer［J］. Clin Lung Cancer, 2005, 7(1): 54-60. DOI: 10.3816/CLC.2005.n.022. ［17］ Gao Y, Liu Z, Zhang X, et al. Inhibition of cytoplasmic GSK3β increases cisplatin resistance through activation of Wnt/βcatenin signaling in A549/DDP cells［J］. Cancer Lett, 2013, 336(1): 231-239. DOI: 10.1016/j.canlet.2013.05.005. ［18］ Cheng H, Liang H, Qin Y, et al. Nuclear betacatenin overexpression in metastatic sentinel lymph node is associated with synchronous liver metastasis in colorectal cancer［J］. Diagn Pathol, 2011, 6: 109. DOI: 10.1186/1746-1596-6-109. ［19］万兵, 郑玉仙, 叶飞君. Wnt/βcatenin信号通路在肝癌耐药中的研究作用［J］. 中国综合临床, 2012, 28(12): 1242-1245. DOI: 10.3760/cma.j.issn.10086315.2012.12.004. ［20］ Xu N, Shen C, Luo Y, et al. Upregulated miR130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatintreated HCC cell［J］. Biochem Biophys Res Commun, 2012, 425(2): 468-472. DOI: 10.1016/j.bbrc.2012.07.127. ［21］ Shen DY, Zhang W, Zeng X, et al. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multidrug resistance of cholangiocarcinoma［J］. Cancer Sci, 2013, 104(10): 1303-1308. DOI: 10.1111/cas.12223. ［22］ Shen DY, Kang JH, Song W, et al. Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspasedependent pathway［J］. Phytother Res, 2011, 25(10): 1519-1526. DOI: 10.1002/ptr.3435. ［23］ Huang GL, Shen DY, Cai CF, et al. βescin reverses multidrug resistance through inhibition of the GSK3β/βcatenin pathway in cholangiocarcinoma［J］. World J Gastroenterol, 2015, 21(4): 1148-1157. DOI: 10.3748/wjg.v21.i4.1148.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Wnt/β-catenin信号通路在肿瘤耐药中的研究进展

Research progress of Wnt/β-catenin signaling pathway in tumor drug resistance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价